IgA Nephropathy Pipeline

Aug 19, 2024

The first horse bearing Novartis’ IgAN treatment has reached the FDA’s approval milestone. FABHALTA is approved for use in treating IgAN patients who are at risk of swift disease progression, as evidenced by a urine protein-to-creatinine ratio of 1.5 g/g or higher. On August 8, the FDA approved the use of Novart...

Jul 22, 2024

Conventional  IgA nephropathy treatments include ACE inhibitors (angiotensin-converting enzyme inhibitors) and ARBs (angiotensin II receptor blockers) to manage symptoms like high blood pressure. The only two FDA-approved treatments for managing IgAN are TARPEYO/KINPEYGO (budesonide) and FILSPARI (sparsentan)....

Nov 05, 2021

IgA Nephropathy (IgAN), also called Berger’s disease, is an autoimmune rare disease affecting the kidneys. It impairs blood filtration in the kidneys' tiny blood channels. An aberrant protein destroys the filtering unit (glomerulus) inside the kidneys, causing IgA Nephropathy. It is estimated that 20–40% of persons...